Patients

ACTBRCA?

ACTBRCA® Open Up Opportunities For PARP Inhibitor

In the medical journey of cancer treatment, precision medicine is recognized as a modern and favored way for healthcare system to take care of cancer patients more easily. Challenges of identifying the right drug to every cancer patient while new drugs are emerging for specific genomic mutations can be tackled strategically by having cancer patients’ unique cancer genomic profiles. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well as USFDA committed from 2018. The wave of precision medicine also increases approvals of companion diagnostics, bringing ACT Genomics’ genomic profiling service on the waiting list of USFDA approval.

Why You Need To Know About Precision Medicine

Top global pharma companies fasten the pace to conduct clinical trials of precision medicine, which requires cancer patients’ genomic information via genomic profiling. This evolution affects most hospitals, so you need to get prepared for the genomic profiling if you are always looking for a new treatment.

   

Clinical Trials Highlights

 http://www.aichuangreng.com/en/clinical_news/list


Can I Use PARP Inhibitors To Destroy My Cancer?

Bearing hardship is not the right vibe in precision medicine, PARP Inhibitors demonstrate how a patient can overcome treatment difficulties less painful by targeting at cancer cell’s vulnerable part-its’ DNA repair functions. Once the DNA repair mechanism of a cancer cell has some gene defects including BRCA and other HRR genes and the feature homologous recombination deficiency (HRD) is formed, it’s time for PARP Inhibitors to clean up the mess. Effective and oral dose as expected, making cancer treatment easy and ovarian and HER2-negative breast cancer patients who previously suffered from the pain of multiple surgeries and ineffective chemotherapies can turn the table on fighting against cancer.


Common Problems In Cancer Treatment

? Chemotherapy and surgery are the only options according to NCCN guideline or single gene test result

? Complicated and metastases, hard to know the appropriate drugs

? Ineffective treatment, and cancer relapse after targeted therapy

? Pursue for immunotherapy, targeted therapy and wondering the effect


More Comprehensive Diagnostic Solutions Than Traditional BRCA Gene Testing 

Through Next Generation Sequencing (NGS), ACTBRCA®  decodes BRCA1/2 cancer genes to map drug options via many clinical researches, not limit to single clinical treatment guideline. ACTBRCA®  controls the growth mechanism from genomic level and enables more treatment strategy with higher success rate. Suitable for ovarian and breast cancer. If single gene test does not bring satisfying result, NGS genomic profiling can detect special genomic mutations for better treatment.


Image title










DNA Repair Gene Testing Can Bring Treatment Advantages As Follows:

? More humanized process : Avoid multiple biopsies and time cost, only few specimen allowing for BRCA1/2 detection at once.

More ideal treatment :  PARP inhibitor evaluation

? Plan medical budget more intelligently : Evaluate options before treatment according to genomic information, to ensure success rate and avoid waste of medical budget.


Listen To The Successful Fighters' Stories

Many cancer patients are diagnosed late stage, and some patients will know precision medicine is because they have medical background or being recommended by physicians. Listen to their stories and help them bring hope to more people.


Cancer Patient Stories :
http://www.aichuangreng.com/en/patient#arc_story

 

癌癥照護

ACTBRCA® 

? Who Can Use : Patients with ovarian cancer or breast cancer

? Specimen Type : Blood or Tumor sample

? Turnaround Time : 14 calenday days after qualified specimen is received




Sources:

- Venkitaraman AR. Annu Rev Pathol 2009; 4: 461-487.

- Lord CJ. et al. Science. 2017 Mar 17;355(6330):1152-1158.

- O'Malley DM. et al. Mol Cancer Ther 2018;17(1 Suppl): Abstract nr LB-A12.

- da Cunha Colombo Bonadio RR. et al. Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s.


日韩av电影,色YEYE高清在线视频,欧美XXZOZO,JAPANESE 18日本护士